<?xml version='1.0' encoding='utf-8'?>
<document id="10783825"><sentence text="P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans."><entity charOffset="25-37" id="DDI-PubMed.10783825.s1.e0" text="erythromycin" /><entity charOffset="72-81" id="DDI-PubMed.10783825.s1.e1" text="talinolol" /><pair ddi="false" e1="DDI-PubMed.10783825.s1.e0" e2="DDI-PubMed.10783825.s1.e0" /><pair ddi="false" e1="DDI-PubMed.10783825.s1.e0" e2="DDI-PubMed.10783825.s1.e1" /></sentence><sentence text="Increased bioavailability of the P-glycoprotein (Pgp) substrates digoxin and cyclosporin due to erythromycin has been observed in vivo"><entity charOffset="65-72" id="DDI-PubMed.10783825.s2.e0" text="digoxin" /><entity charOffset="77-88" id="DDI-PubMed.10783825.s2.e1" text="cyclosporin" /><entity charOffset="96-108" id="DDI-PubMed.10783825.s2.e2" text="erythromycin" /><pair ddi="false" e1="DDI-PubMed.10783825.s2.e0" e2="DDI-PubMed.10783825.s2.e0" /><pair ddi="false" e1="DDI-PubMed.10783825.s2.e0" e2="DDI-PubMed.10783825.s2.e1" /><pair ddi="false" e1="DDI-PubMed.10783825.s2.e0" e2="DDI-PubMed.10783825.s2.e2" /><pair ddi="false" e1="DDI-PubMed.10783825.s2.e1" e2="DDI-PubMed.10783825.s2.e1" /><pair ddi="false" e1="DDI-PubMed.10783825.s2.e1" e2="DDI-PubMed.10783825.s2.e2" /></sentence><sentence text=" The aim of the present study was to investigate the effect of orally administered erythromycin on the oral bioavailability of the beta-blocker talinolol"><entity charOffset="83-95" id="DDI-PubMed.10783825.s3.e0" text="erythromycin" /><entity charOffset="144-153" id="DDI-PubMed.10783825.s3.e1" text="talinolol" /><pair ddi="false" e1="DDI-PubMed.10783825.s3.e0" e2="DDI-PubMed.10783825.s3.e0" /><pair ddi="false" e1="DDI-PubMed.10783825.s3.e0" e2="DDI-PubMed.10783825.s3.e1" /></sentence><sentence text=" Talinolol is a suitable model compound for Pgp drug-drug interaction studies due to its Pgp-related active intestinal secretion and lack of any significant metabolism"><entity charOffset="1-10" id="DDI-PubMed.10783825.s4.e0" text="Talinolol" /></sentence><sentence text="" /><sentence text="In a randomized crossover study, the oral pharmacokinetics of talinolol (50 mg) after a concomitant single oral dose of erythromycin (2 g) or placebo were investigated in 9 healthy men"><entity charOffset="62-71" id="DDI-PubMed.10783825.s6.e0" text="talinolol" /><entity charOffset="120-132" id="DDI-PubMed.10783825.s6.e1" text="erythromycin" /><pair ddi="false" e1="DDI-PubMed.10783825.s6.e0" e2="DDI-PubMed.10783825.s6.e0" /><pair ddi="false" e1="DDI-PubMed.10783825.s6.e0" e2="DDI-PubMed.10783825.s6.e1" /></sentence><sentence text=" Concentrations of talinolol were measured in serum and urine by HPLC"><entity charOffset="19-28" id="DDI-PubMed.10783825.s7.e0" text="talinolol" /></sentence><sentence text="" /><sentence text="The area under the curve of talinolol serum concentrations from 0 to 24 h (AUC(0-24)) and the maximum serum concentrations (Cmax) were significantly increased after administration of erythromycin compared to placebo"><entity charOffset="183-195" id="DDI-PubMed.10783825.s9.e0" text="erythromycin" /></sentence><sentence text=" t(max) values were significantly reduced" /><sentence text=" The renal clearance (CLR) of talinolol was unchanged after co-administration of erythromycin and there was a small but statistically significant decrease in elimination half-life (t1/2)"><entity charOffset="30-39" id="DDI-PubMed.10783825.s11.e0" text="talinolol" /><entity charOffset="81-93" id="DDI-PubMed.10783825.s11.e1" text="erythromycin" /><pair ddi="false" e1="DDI-PubMed.10783825.s11.e0" e2="DDI-PubMed.10783825.s11.e0" /><pair ddi="false" e1="DDI-PubMed.10783825.s11.e0" e2="DDI-PubMed.10783825.s11.e1" /></sentence><sentence text=" Serum pharmacokinetics correlate with the results derived from urine concentration measurement" /><sentence text=" One subject suffered from moderate diarrhea after erythromycin and was excluded from the analysis"><entity charOffset="51-63" id="DDI-PubMed.10783825.s13.e0" text="erythromycin" /></sentence><sentence text="" /><sentence text="We suggest that the increase in oral bioavailability of talinolol after concomitant erythromycin is caused by increased intestinal net absorption due to Pgp inhibition by erythromycin"><entity charOffset="56-65" id="DDI-PubMed.10783825.s15.e0" text="talinolol" /><entity charOffset="84-96" id="DDI-PubMed.10783825.s15.e1" text="erythromycin" /><entity charOffset="171-183" id="DDI-PubMed.10783825.s15.e2" text="erythromycin" /><pair ddi="false" e1="DDI-PubMed.10783825.s15.e0" e2="DDI-PubMed.10783825.s15.e0" /><pair ddi="false" e1="DDI-PubMed.10783825.s15.e0" e2="DDI-PubMed.10783825.s15.e1" /><pair ddi="false" e1="DDI-PubMed.10783825.s15.e0" e2="DDI-PubMed.10783825.s15.e2" /><pair ddi="false" e1="DDI-PubMed.10783825.s15.e1" e2="DDI-PubMed.10783825.s15.e1" /><pair ddi="false" e1="DDI-PubMed.10783825.s15.e1" e2="DDI-PubMed.10783825.s15.e2" /></sentence><sentence text="" /></document>